Exercise capacity of hemodialysis patients following recombinant human erythropoietin treatment
- Resource Type
- Authors
- Kenneth H. Pitetti; Kathryn D. Campbell Ed.D.; Dennis L. Ross; K R N Debra Wimberley
- Source
- Sports Medicine, Training and Rehabilitation. 3:261-269
- Subject
- Mean arterial pressure
medicine.medical_specialty
medicine.diagnostic_test
business.industry
Anemia
medicine.medical_treatment
Rehabilitation
Public Health, Environmental and Occupational Health
VO2 max
Hematocrit
medicine.disease
Surgery
Erythropoietin
Anesthesia
Heart rate
medicine
Hemodialysis
Treadmill
business
medicine.drug
- Language
- ISSN
- 1057-8315
The purpose of this study was to determine if correction of anemia by recombinant human erythropoietin (r‐HuEPO) treatment would improve the exercise capacity of patients maintained on chronic hemodialysis. Eleven patients (age, 55 ± 13 years) underwent a modified Balke treadmill test before and after r‐HuEPO treatment. A small but significant (p ≤0.05) increase in hematocrit (Hct; 26.7 ± 3% to 34.3 ± 0%) and hemoglobin (Hb; 8.8 ± 0.9 to 11.2 ± 0.8 mg·dl−1) was observed following treatment. No significant change was observed in either submaximal mean arterial pressure or heart rate (HR) at a defined work rate. Although all subjects subjectively reported (verbally) that they felt better, no statistically significant increase was noted in peak oxygen uptake (1078 ± 201 to 1090 ± 234 ml·min−1) or total test time (11.4 ± 4 to 12.2 ± 5 min). No significant change was seen in peak HR (143 ± 15 to 137 ± 21 beats/min) or peak ventilation (46 ± 16 to 48 ± 13 L·min−1). Our results differ from those of previous stud...